Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) is now available.
Clarity Pharmaceuticals announced that its SECuRE Phase II Cohort Expansion trial of 67Cu-SAR-bisPSMA in prostate cancer will continue without any protocol changes following a Safety Review Committee assessment, with interim data from nine heavily pre-treated participants showing a favourable safety profile and no renal or ECG toxicity. Efficacy signals are encouraging, with all six participants who had multiple post-treatment PSA assessments experiencing PSA declines, two-thirds achieving at least a 50% reduction and one-third exceeding an 80% reduction, including one patient with bone metastases who reached undetectable PSA and no radiologically detectable disease after three cycles; the company will continue enrolment through 2026 and is progressing plans for a Phase III registrational trial, underscoring the program’s potential to advance in the prostate cancer treatment landscape.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd (ASX: CU6) is a clinical-stage radiopharmaceutical company focused on developing next‑generation targeted copper-based therapies to improve treatment outcomes for cancer patients, with a particular emphasis on prostate cancer imaging and therapy.
Average Trading Volume: 2,255,400
Technical Sentiment Signal: Buy
Current Market Cap: A$1.43B
See more insights into CU6 stock on TipRanks’ Stock Analysis page.